Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-tumor Response in a Syngeneic Tumor Model

Autor: Paul L. Hallenbeck, Sunil Chada, Neil Sankar, Aman Chauhan

Publikováno v: Endocrine Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::310ccb59952fa5e6048848aebf1a92ea
https://doi.org/10.1530/endoabs.89.b5

Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Autor: Jeffrey Bacha, Dennis Brown, Sarath Kanekal, Neil Sankar, Lorena Lopez, Noymi Yam, Lars Wagner, James Geller, Markos Leggas, Patrick Thompson, Javier Osterheld

Publikováno v: Cancer Research. 83:CT135-CT135

Background: Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. IRN-IV is also used off-label to treat a range of adult and pediatric tumors including recurrent Ewing sarcoma, rhabdomyosarcoma, neur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8b2a16dea3567390bfd01a4bbfa5273
https://doi.org/10.1158/1538-7445.am2023-ct135

Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Autor: James Geller, Patrick Thompson, Javier Oesterheld, Dennis M. Brown, Jeffrey Bacha, Sarath Kanekal, Lorena Lopez, Markos Leggas, Neil Sankar, Noymi Yam, Lars M. Wagner

Publikováno v: Cancer Research. 82:CT256-CT256

Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. IRN-IV is also widely used off-label for a range of adult and pediatric solid tumors including recurrent Ewing sarcoma, rhabdomyosarcoma, neurobla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5956a4e3a92592ee5afb343c3fd9b285
https://doi.org/10.1158/1538-7445.am2022-ct256

CTNI-08. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION

Autor: Jeffrey A. Bacha, Wang Shen, Sophia Frentzas, Helen Wheeler, Peony Yu, Wang Zhen Zhong, Gary Richardson, Chinglin Lai, Neil Sankar, Harry Pedersen, Sarath Kanekal, Kathy Skoff, Sanjeev Redkar, Dennis Brown, Ian Nisbet

Publikováno v: Neuro Oncol

Mutations causing errant ErbB activation are implicated in many cancers, including tumors correlated with high incidence of CNS metastasis. ErbB family member “crosstalk” is associated with rapid development acquired resistance to ErbB TKIs, part

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::143611be4ea4e4a86b6bc4e412d2092d
https://europepmc.org/articles/PMC7650483/

Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark

Autor: Neil Sankar, Robert Sikorski, Vera Ehrenstein, John F. Acquavella, Ibrahim Qazi, Søren L. Andersen, Alma B Pedersen

Publikováno v: Ehrenstein, V, Andersen, S L, Qazi, I, Sankar, N, Pedersen, A B, Sikorski, R & Acquavella, J F 2017, ' Tenosynovial Giant Cell Tumor : Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark ', Journal of Rheumatology, vol. 44, no. 10, pp. 1476-1483 . https://doi.org/10.3899/jrheum.160816

Objective.Tenosynovial giant cell tumor (TGCT) is a rare benign proliferative and inflammatory disease arising from synovia of joints, bursae, or tendon sheaths. We aimed to estimate incidence rate and prevalence of TGCT in Denmark, to describe patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::213be15109e6c77e3a7cf1b6c6c8b4a4
https://doi.org/10.3899/jrheum.160816